The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels
Open accessAbstract
Drugs for cancer therapy belong to different categories of chemical substances. The cellular targets for the therapeutic efficacy are often not unambiguously identified. Here, we describe the process of ribosome biogenesis as a target of a large variety of chemotherapeutic drugs. We determined the inhibitory concentration of 36 chemotherapeutic drugs for transcription and processing of ribosomal RNA by in vivo labeling experiments. Inhibitory drug concentrations were correlated to the loss of nucleolar integrity. The synergism of drugs inhibiting ribosomal RNA synthesis at different levels was studied. Drugs inhibited ribosomal RNA synthesis either at the level of (i) rRNA transcription (e.g. oxaliplatin, doxorubicin, mitoxantrone, methotrexate), (ii) early rRNA processing (e.g. camptothecin, flavopiridol, roscovitine), or (iii) late rRNA processing (e.g. 5-fluorouracil, MG-132, homoharringtonine). Blockage of rRNA transcription or early rRNA processing steps caused nucleolar disintegration, whereas blockage of late rRNA processing steps left the nucleolus intact. Flavopiridol and 5-fluorouracil showed a strong synergism for inhibition of rRNA processing. We conclude that inhibition of ribosome biogenesis by chemotherapeutic drugs potentially may contribute to the efficacy of therapeutic regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Disruption of p53 in human cancer cells alters the responses to therapeutic agents.
Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., & Vogelstein, B. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6863 · Cited by 1,044
The Chemical Genomic Portrait of Yeast: Uncovering a Phenotype for All Genes
Hillenmeyer, M. E., Fung, E., Wildenhain, J., Pierce, S. E., Hoon, S., Lee, W., Proctor, M., St.Onge, R. P., Tyers, M., Koller, D., et al. (2008) · Science · doi:10.1126/science.1150021 · Cited by 1,003
Rubbi, C. P. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg579 · Cited by 811
RNA Exosome Depletion Reveals Transcription Upstream of Active Human Promoters
Preker, P., Nielsen, J., Kammler, S., Lykke-Andersen, S., Christensen, M. S., Mapendano, C. K., Schierup, M. H., & Jensen, T. H. (2008) · Science · doi:10.1126/science.1164096 · Cited by 791
Regulation of HDM2 activity by the ribosomal protein L11
Lohrum, M. A. E., Ludwig, R. L., Kubbutat, M. H. G., Hanlon, M., & Vousden, K. H. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00134-x · Cited by 623
Dai, M.-S., Zeng, S. X., Jin, Y., Sun, X.-X., David, L., & Lu, H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7654-7668.2004 · Cited by 489
Lum, P. Y., Armour, C. D., Stepaniants, S. B., Cavet, G., Wolf, M. K., Butler, J. S., Hinshaw, J. C., Garnier, P., Prestwich, G. D., Leonardson, A., et al. (2004) · Cell · doi:10.1016/s0092-8674(03)01035-3 · Cited by 481
Metabolism and mechanism of action of 5-fluorouracil
Parker, W. B., & Cheng, Y. C. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90056-8 · Cited by 451
Dynamic Sorting of Nuclear Components into Distinct Nucleolar Caps during Transcriptional Inhibition
Shav-Tal, Y., Blechman, J., Darzacq, X., Montagna, C., Dye, B. T., Patton, J. G., Singer, R. H., & Zipori, D. (2005) · Molecular Biology of the Cell · doi:10.1091/mbc.e04-11-0992 · Cited by 400
Cited by
Boulon, S., Westman, B. J., Hutten, S., Boisvert, F.-M., & Lamond, A. I. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.024 · Cited by 1,103
The nucleolus as a multiphase liquid condensate
Lafontaine, D. L. J., Riback, J. A., Bascetin, R., & Brangwynne, C. P. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0272-6 · Cited by 1,051
Ribosome biogenesis in cancer: new players and therapeutic avenues
Pelletier, J., Thomas, G., & Volarević, S. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.104 · Cited by 812
Ribosomal proteins: functions beyond the ribosome
Zhou, X., Liao, W.-J., Liao, J.-M., Liao, P., & Lu, H. (2015) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjv014 · Cited by 743
Composition-dependent thermodynamics of intracellular phase separation
Riback, J. A., Zhu, L., Ferrolino, M. C., Tolbert, M., Mitrea, D. M., Sanders, D. W., Wei, M.-T., Kriwacki, R. W., & Brangwynne, C. P. (2020) · Nature · doi:10.1038/s41586-020-2256-2 · Cited by 691
Drygin, D., Lin, A., Bliesath, J., Ho, C. B., O'Brien, S. E., Proffitt, C., Omori, M., Haddach, M., Schwaebe, M. K., Siddiqui-Jain, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1728 · Cited by 618
Inhibiting eukaryotic transcription: which compound to choose? How to evaluate its activity
Bensaude, O. (2011) · Transcription · doi:10.4161/trns.2.3.16172 · Cited by 574
Bruno, P. M., Liu, Y., Park, G. Y., Murai, J., Koch, C. E., Eisen, T. J., Pritchard, J. R., Pommier, Y., Lippard, S. J., & Hemann, M. T. (2017) · Nature Medicine · doi:10.1038/nm.4291 · Cited by 519
Baßler, J., & Hurt, E. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-110817 · Cited by 414
Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy
Kang, J., Brajanovski, N., Chan, K. T., Xuan, J., Pearson, R. B., & Sanij, E. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00728-8 · Cited by 408
NPM1-mutated acute myeloid leukemia: from bench to bedside
Falini, B., Brunetti, L., Sportoletti, P., & Martelli, M. P. (2020) · Blood · doi:10.1182/blood.2019004226 · Cited by 337
A Targeting Modality for Destruction of RNA Polymerase I that Possesses Anticancer Activity
Peltonen, K., Colis, L., Liu, H., Trivedi, R., Moubarek, M. S., Moore, H. M., Bai, B., Rudek, M. A., Bieberich, C. J., & Laiho, M. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.009 · Cited by 314
Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance
Elhamamsy, A. R., Metge, B. J., Alsheikh, H. A., Shevde, L. A., & Samant, R. S. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-4087 · Cited by 300
The Influence of Cell Cycle Regulation on Chemotherapy
Sun, Y., Liu, Y., Ma, X., & Hu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136923 · Cited by 290
Nucleolar stress with and without p53
James, A., Wang, Y., Raje, H., Rosby, R., & DiMario, P. (2014) · Nucleus · doi:10.4161/nucl.32235 · Cited by 285
Nucleolar Stress: hallmarks, sensing mechanism and diseases
Yang, K., Yang, J., & Yi, J. (2018) · Cell Stress · doi:10.15698/cst2018.06.139 · Cited by 283
Long Noncoding RNA: Genome Organization and Mechanism of Action
Akhade, V. S., Pal, D., & Kanduri, C. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-5203-3_2 · Cited by 266
The nucleolus: structure/function relationship in RNA metabolism
Hernandez‐Verdun, D., Roussel, P., Thiry, M., Sirri, V., & Lafontaine, D. L. J. (2010) · WIREs RNA · doi:10.1002/wrna.39 · Cited by 261
The Ribosome Biogenesis—Cancer Connection
Penzo, M., Montanaro, L., Treré, D., & Derenzini, M. (2019) · Cells · doi:10.3390/cells8010055 · Cited by 242
“[53] strengthened this concept by demonstrating that the alkylating and intercalating agents, antimetabolites, and topoisomerase and kinase inhibitors currently used for treating cancer also induce ribosome biogenesis inhibition, thus contributing to their toxic action on cancer cells.”
BackgroundImportin 7 and Exportin 1 Link c-Myc and p53 to Regulation of Ribosomal Biogenesis
Golomb, L., Bublik, D. R., Wilder, S., Nevo, R., Kiss, V., Grabusic, K., Volarevic, S., & Oren, M. (2012) · Molecular Cell · doi:10.1016/j.molcel.2011.11.022 · Cited by 137
“Similar changes were observed upon inhibition of rRNA transcription or early rRNA processing (Burger et al., 2010).”
Hubackova, S., Davidova, E., Boukalova, S., Kovarova, J., Bajzikova, M., Coelho, A., Terp, M. G., Ditzel, H. J., Rohlena, J., & Neuzil, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2224-7 · Cited by 58
Mitoxantrone Inhibits HIF-1α Expression in a Topoisomerase II–Independent Pathway
Toh, Y.-M., & Li, T.-K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0235 · Cited by 32
“Consistently, our results (data not shown) and a recent report show that mitoxantrone decreases rRNA expression (40).”
ResultEXOSC10/Rrp6 is essential for the eight-cell embryo/morula transition
Petit, F. G., Jamin, S. P., Kernanec, P.-Y., Becker, E., Halet, G., & Primig, M. (2022) · Developmental Biology · doi:10.1016/j.ydbio.2021.12.010 · Cited by 20
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response
Tagnères, S., Santo, P. E., Radermecker, J., Rinaldi, D., Froment, C., Provost, Q., Bongers, M., Capeille, S., Watkins, N., Marcoux, J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52659-x · Cited by 15
Metadata
- Authors
- Burger, K., Mühl, B., Harasim, T., Rohrmoser, M., Malamoussi, A., Orban, M., Kellner, M., Gruber-Eber, A., Kremmer, E., Hölzel, M., & Eick, D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 285
- Issue
- 16
- Pages
- 12416-12425
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1980373840
- Cited by
- 458
- References
- 35
- FWCI
- 6.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.